Drug intelligence / Profile preview

MB-GBM-101

Development stage: Preclinical
Lead developer: Mercury Bio
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

MB-GBM-101 is an experimental small interfering RNA (siRNA) therapeutic being developed by Mercury Bio (Mercury Holdings) for the treatment of glioblastoma. The drug utilizes RNA interference (RNAi) to silence specific target genes involved in the progression of glioblastoma cells. Mercury Bio's platform focuses on the delivery of such payloads across the blood-brain barrier (BBB) to reach intracranial targets. As of early 2024, MB-GBM-101 is in the preclinical stage of development.

Beyond the preview

Go deeper on MB-GBM-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-GBM-101.

Explore the full profile